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Abstract: A range of precious metal complexes incorporating either benzyl or carbaboranyl functionalised tethered N-
heterocyclic carbenes have been prepared, including single X-ray crystallography for one new complex. The library has been 
screened for their anti-cancer potential against colorectal, ovarian, cisplatin-resistant ovarian and breast cancer cell lines and 
their selectivity determined by comparing the cytotoxicity towards normal cells. Overall, these complexes show significant 
selectivity for ovarian carcinoma, and are up to 3-fold more cytotoxic than cisplatin against cisplatin-resistant human ovarian 
carcinoma. Upon replacing the benzyl moiety of the NHC ligand with a carbaboranyl there is a general increase observed in the 
potency of the complexes, with the cytotoxicity of the ruthenium complex increasing by >16-fold against human ovarian 
carcinoma. Generally, the rhodium complex with the benzyl tethered NHC shows the greatest selectivity for cancer, with a 
selectivity index of 15, which is >2x, >9x and >6x higher than that of cisplatin, carboplatin and oxaliplatin, respectively. 
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Introduction 
To date, platinum-based therapeutics still dominate as 
clinical drugs for the treatment of cancer. Although these 
complexes, especially cisplatin, have been crucial in the 
fight against cancer, there are major drawbacks 
associated with their use.[1,2] These include severe 
patient side effects due to the lack of cancer cell 
selectivity and only a small range of tumours are 
treatable due to increases in cancer cell resistance. Such 
drawbacks have lead researchers to design and test new 
transition metal complexes with potentially different 
modes of action, in order to combat the issues of normal 
cell toxicity and cancer resistance. To date, 
organometallic complexes of ruthenium (Ru), iridium (Ir) 
and rhodium (Rh) have shown to be promising 
candidates.[3] 
Since their discovery, N-heterocyclic carbenes (NHCs) 
have emerged as a versatile class of ligands which can be 
easily modified.[4] Such modifications have included the 
addition of sterically demanding functional groups for the 
stabilisation of a range of metal-NHCs, which have been 
reported for their use as catalysts, antimicrobial agents 
and anticancer agents.[4–7] Silver-NHCs once dominated 
the field of metal-NHCs in the treatment of cancer,[8–11] 
however, in recent years the use of precious metal 
complexes incorporating NHCs have shown significance 
and this is a growing research field.[12–16] In particular, 
the work by Metzler-Nolte et al.[17–20] and Meggers et 
al.[21,22] on COD (cyclooctadiene) iridium(I)-NHC 
complexes has been fundamental in understanding how 
the complexes charge and functionality of the NHC ligand 
can affect in vitro activities. These complexes incorporate 
simple NHC ligands and can exhibit up to nanomolar 
activity, however, they slowly oxidise to Ir(III). More 
recently, arene Ru(II)-NHC[23] and arene Ir(III)-NHC[24] 
complexes have emerged as new classes of anticancer 
metal-NHC compounds, showing increased activity 
against tumours and were report to cause cell death 
through apoptosis related pathways. Although rhodium 
has been reported to have potential as an alternative 
metal for platinum,[25] to date the anticancer potential 
of arene rhodium(I)/(III)-NHC complexes is a new 
research field, with the major of work published on their 
activity as catalysts.[26] 
Carbaboranyl moieties have been used to functionalize 
phosphonates and their abilities to inhibit 
acetylcholinestrerase[27] and treat E. Coli[28] have been 
assessed. Although it was proposed such compounds 
could treat bone tumours, the biological tests were not 
conducted.[29] In 1993, the first oligonucleotide was 
functionalized with carbaboranyls and these were further 
modified, yet again, no biological data was 
presented.[30,31] Dicarbaboranyl compounds have also 
been designed, and show an increase in cytotoxicity on 
addition of the second carbaboranyl, however, the 
compounds’ activities are only in the millimolar 
range.[32] The use of metallacarboranes is a growing area 
of research,[33] and several reports have highlighted 
their nanomolar potency towards human ovarian 
carcinoma (A2780).[34,35] Compounds such as these are 
high in 10B content, and have the potential to be used in 
 
 
boron neutron capture therapy (BNCT).[36] Willans and 
co-workers have synthesised new NHC ligands with a 
tethered carbaboranyl arms, and reported the 
complexation reactions with Ru, Ir, Rh and Ag.[37–39] In 
2019, the group reported the Ag-NHC tethered 
carbaboranyl complexes to have in vitro activities which 
are one order of magnitude more cytotoxic than the Ag-
NHC benzyl derivatives, when tested against the isogenic 
human colorectal cancer HCT116 p53+/+ (p53-wildtype) 
and HCT116 p53-/- (p53-null).[39]  
In this study, we have prepared a range of precious metal 
complexes incorporating a tethered benzyl or 
carbaboranyl pendant arm on the NHC. We report the 
synthesis of a new benzyl tether NHC ligand (ligand 1), 
and the synthesis of two new precious metal complexes 
by complexation of ligand 1 to either p-cymene Ru(II) (1) 
or Cp* Rh(III) (6). An additional complex was synthesised 
by complexation of a known carbaboranyl tethered NHC 
ligand and COD Ir(III) (5). All other ligands and complexes 
have been published by Willans and co-workers,[37–39] 
and herein we report their stability in dimethyl sulfoxide 
(DMSO) over a period of 72 h at room temperature. The 
p-cymene Ru(II) complexes (1-2), Cp* Ir (III)/Rh(III) 
complexes (3, 4, 6 and 7) and COD Ir(I)/Rh(I) complexes 
(5 and 8) were screened for their potency against human 
colorectal carcinoma p53-wildtype (HCT116 p53+/+), 
human ovarian carcinomas: cisplatin-sensitive (A2780) 
and cisplatin-resistant (A2780cisR), and human breast 
adenocarcinoma (MCF-7). In order to assess the 
complexes’ selectivity towards cancerous cells, the 
complexes were screened against human prostate cells 
(PNT2). The results highlight a general increase in potency 
when the benzyl moiety is replaced with a carbaboranyl 
group, with >16-fold increase observed for the ruthenium 
complexes.  
Material and methods 
1.1 General 
Anhydrous solvents were prepared by passing over 
activated alumina to remove water, copper catalyst to 
remove oxygen and molecular sieves to remove any 
remaining water, via the Dow-Grubbs solvent system, 
and then freeze-pump-thaw degassed prior to use. 
Decaborane was purchased from KatChem and all other 
chemicals used in this work were bought from either 
Sigma Aldrich or Alfa and used without further 
purification. 
1.2 X-ray crystallography  
X-ray diffraction data was collected on an Agilent 
SuperNova diffractometer fitted with an Atlas CCD 
detector with Mo- Kα radiation (λ = 0.71073 Å). The 
crystal was mounted under oil on nylon fibres and data 
collected at 120 K. An empirical absorption correction 
using spherical harmonics was used, the structures were 
solved by direct methods using SHELXT[40] and refined 
by full-matrix least squares on F2 using SHELXL[41] 
interfaced through the program Olex2.[42] Molecular 
graphics for all structures were generated using 
Mercury.[43] 
1.3 Synthesis 
Complexes 2, 3, 4, 7[37] and 8[38] were prepared by 
published literature methods.  
Ligand 1. 2-Phenylethylbromide (500 mg, 2.70 mmol), 1-
methylimidazole (219 mg, 2.67 mmol) and MeCN (5 mL) 
were added to a Schlenk flask and heated at reflux for 18 
hours. The reaction was cooled to room temperature and 
the solvent removed in vacuo. The residue was 
recrystallized from DCM (5 mL)/Et2O (30 mL) to yield a 
pale yellow oil. This was cooled to 4°C to afford the 
product as an off-white solid (620 mg, 2.32 mmol, 86 %). 
1H NMR (300 MHz, CDCl3, δ): 10.08 (s, imidazolium 
NCHN), 7.47 (t, 1H, 3J(1H-1H) = 3 Hz, NCH), 7.34 (t, 1H, 
3J(1H-1H) = 3 Hz, NCH), 7.22-7.11 (m, 5H, ArCH), 4.55 (t, 
2H, 3J(1H-1H) = 6 Hz, CH2), 3.94 (s, 3H, CH3), 3.18 (t, 2H, 
3J(1H-1H) = 6 Hz, CH2). 13C{1H} NMR (75 MHz, CDCl3, δ): 
137.1 (Q, NCN), 135.8 (Q, ArC), 128.9 (NCH), 128.8 (NCH), 
127.4 (ArCH), 123.4 (ArCH), 122.5 (ArCH), 51.0 (NCH2), 
36.6 (CH2), 36.5 (NCH3). HRMS (ESI+): m/z [C12H15N2]+ 
187.1235, calcd for [M − Br]+ 187.1249. 
 
Complex 1: To a Schlenk flask was added the ligand 1 (50 
mg, 0.19 mmol), Ag2O (22 mg, 0.095 mmol), [Ru(p-
cymene)Cl2]2 (58 mg, 0.095 mmol), anhydrous DCM (5 
mL) and anhydrous MeOH (0.1 mL) along with a small 
number of 4 Å molecular sieves. The reaction was heated 
at 40 °C for 3 hours. The reaction was cooled to room 
temperature, filtered over Celite and further washed with 
DCM (3 × 5 mL). The solvent was removed in vacuo and 
the residue subjected to column chromatography on 
silica, using a gradient elution with DCM/MeOH (2%) to 
afford an orange solid. Recrystallization from acetone (5 
mL)/ pentane (30 mL) afforded the product as an orange 
powder (69 mg, 0.14 mmol, 74 %). 1H NMR (500 MHz, 
CDCl3, ): Major isomer; 7.38-7.22 (m, 5H, benzyl), 7.08 
(d, 1H, 3J(1H-1H) = 2 Hz, NCH), 7.02 (d, 1H, 3J(1H-1H) = 2 Hz, 
NCH), 5.29 (m, 2H, p-cymene ArH), 5.05 (d, 1H, 3J(1H-1H) 
= 5 Hz, p-cymene ArH), 4.92 (m, 1H, NCH2), 4.84 (d, 1H, 
3J(1H-1H) = 5 Hz, p-cymene ArH), 4.08 (m, 1H, NCH2), 3.97 
(s, 3H, CH3), 3.34 (m, 1H, CH2), 2.97 (m, 1H, CH2), 2.88 
(septet, 1H, 3J(1H-1H) = 10 Hz, p-cymene CH(CH3)2), 1.95 
(s, 3H, p-cymene CH3), 1.20 (d, 6H, 3J(1H-1H) = 5 Hz, p-
cymene CH(CH3)2). 13C{1H} NMR (125 MHz, CDCl3, δ): 
174.0 (Q, Ccarbene), 138.6 (Q, ArC), 129.3 (NCH), 128.8 
(NCH), 126.8 29 (ArCH), 124.1 (ArCH), 121.8 (ArCH), 109.0 
(Q, p-cymene), 99.2 (Q, p-cymene), 85.1-84.8 (p-cymene 
ArCH), 82.7/82.4 (p-cymene ArCH), 53.1 (NCH2), 39.7 
 
 
(NCH3), 37.9 (CH2), 30.7 (CH(CH3)2), 22.7-22.5 (CH(CH3)2), 
18.7 (p-cymene CH3). HRMS (ESI+): m/z [C22H28N2RuCl]+ 
457.0995, calcd for [M − Cl]+ 457.0982. 
 
Complex 5: Ligand 5[37] (29.6 mg, 0.0894 mmol), Ag2O 
(10.6 mg, 0.0457 mmol), [Ir(COD)Cl]2 (30.1 mg, 0.0448 
mmol), activated 4 Å molecular sieves and DCM (5 mL) 
were combined in an ampoule and heated to 45 °C for 19 
hours under nitrogen. The reaction mixture was filtered 
through cotton wool and twice through celite, and the 
filtrate reduced in vacuo. The residue was recrystallized 
from acetone and cold pentane to yield the produce as a 
yellow solid (26.9 mg, 0.046 mmol, 51%). 1H NMR (400 
MHz, CDCl3, δ): 6.82-6.78 (m, 2H, NCH), 5.01 (td, 1H, 
3J(1H-1H) = 12.7 and 4J(1H-1H) = 3.9 Hz, NCH2), 4.69-4.54 
(m, 2H, COD-CH), 4.02 (s, 1H, carbaboranyl-CH), 3.97 
(ddd, 1H 3J(1H-1H) = 13.1 and 11.7, and 4J(1H-1H) = 6.2 Hz, 
NCH2), 3.92 (s, 3H, NCH3), 3.27-3.15 (m, 1H, CH2), 3.02 – 
2.93 (m, 1H, COD-CH), 2.82 – 2.76 (m, 1H, COD-CH), 2.59 
(ddd, 1H, 3J(1H-1H) = 14.7 and 12.5, and 4J(1H-1H) = 6.2 Hz, 
CH2), 2.35 – 2.19 (m, 5H, COD-CH2), 1.89 – 1.81 (m, 1H, 
COD-CH2), 1.76 – 1.60 (m, 4H, COD-CH2). 11B NMR (96 
MHz, CDCl3, δ): -2.39 (1B), -5.13 (1B), -9.00 (2B), -11.27 
(2B), -12.79 4B). 13C{1H} NMR (101 MHz, CDCl3, δ): 181.5 
(Q, Ccarbene), 122.2 (NCH), 120.4 (NCH), 86.3 (COD-CH), 
85.6 (COD-CH), 72.2 (Q, carbaboranyl), 63.4 
(carbaboranyl-CH), 52.7 (COD-CH), 52.2 (COD-CH), 49.2 
(NCH2), 38.2 (CH2), 37.6 (NCH3), 34.0 (COD-CH2), 33.4 
(COD-CH2), 30.0 (COD-CH2), 29.2 (COD-CH2). HRMS (ESI+): 
m/z [C16H32B10IrN2]+ 553.3309, calcd for [M-Cl]+ 553.3198. 
 
Complex 6: To a Schlenk flask was added the ligand 1 (50 
mg, 0.19 mmol), Ag2O (22 mg, 0.095 mmol), [Rh(Cp*)Cl2]2 
(59 mg, 0.095 mmol) and anhydrous DCM (5 mL), along 
with some 4 Å molecular sieves. The reaction was heated 
at 40 °C for 16 hours, filtered through Celite and washed 
with DCM (3 × 5 mL). The solvent was removed from the 
filtrate in vacuo and the residue was recrystallised from 
acetone (5 mL)/ pentane (30 mL), filtered and dried in 
vacuo to yield the product as an orange solid (86 mg, 0.17 
mmol, 92 %). 1H NMR (300 MHz, CDCl3, δ): 7.50-7.15 (m, 
5H, benzyl), 7.02-6.97 (m, 2H, NCH), 5.20 (m, 1H, NCH2), 
4.06-4.04 (s, 3H, NCH3) 3.92 (m, 1H, NCH2), 3.51 (m, 1H, 
CH2) 2.96 (m, 1H, CH2), 1.62-1.58 (br. s, 15H, Cp* CH3). 
13C{1H} NMR (75 MHz, CDCl3, δ): 138.7 (Q, ArC), 129.4 
(ArCH), 128.7 (ArCH), 126.7 (ArCH), 124.5 (NCH), 122.5 
(NCH), 96.3 (Q, d, 1J(Rh-C) = 15 Hz, Cp*), 52.5 (NCH2), 39.3 
(NCH3), 38.2 (NCH2), 9.8-9.6 (Cp* CH3). HRMS (ESI+): m/z 
[C22H29N2RhCl]+ 459.1074, calcd for [M − Cl]+ 459.1069. 
1.4 DMSO stability studies 
10 mg of all complexes were dissolved in 0.6 mL of d6-
DMSO and 1H NMR and 11B NMR spectra recorded after 
0, 1, 2, 4, 6, 24 and 72 hours. All measurements were 
recorded either a Bruker AV4 NEO 500 or Bruker AV4 NEO 
500-CP NMR spectrometer at 25 °C. 
1.5 Chemosensitivity 
Chemosensitivity studies were performed against human 
colorectal adenocarcinoma p53-wildtype (HCT116 
p53+/+), cisplatin-sensitive human ovarian carcinoma 
(A2780), cisplatin-resistant human ovarian carcinoma 
(A2780cisR) and human breast adenocarcinoma (MCF-7). 
Additionally, growth inhibitory effects were also tested 
against normal prostate cell line, PNT2. All cell lines were 
provided by the Institute of Cancer Therapeutics, 
University of Bradford and were routinely maintained as 
monolayer cultures in RPMI 1640 media supplemented 
with 10% foetal calf serum, sodium pyruvate (1 mM) and 
L-glutamine (2 mM). All assays were conducted in 96-well 
round bottom plates, with control lanes for media and 
100% cell growth. Cell concentrations of 1 x 104 cells/mL 
were used, and 100 L (or 100 L media in control lane 1) 
of cell suspension were incubated for 24 h at 37 °C and 
5% CO2 prior to drug exposure. Cisplatin (CDDP), 
carboplatin (CARB), oxaliplatin (OXA) and complexes 1-8 
were all dissolved in dimethylsulfoxide (DMSO) to 
provide fresh stock solutions for each run (100 mM). 
These were further diluted with complete media to 
provide a range of concentrations (final concentration 
DMSO <0.1% v/v). After 24 h incubation, 100 L of the 
drug/media solutions were added to the plates in 
columns 3-12 (100 L media in lanes 1 and 2 for controls), 
and then the plates incubated for 96 h at 37°C and 5% 
CO2. After 96 h, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (20 L, 5 mg/mL) 
was added to each well and incubated for 3 h at 37 °C and 
5% CO2. All solutions were removed via pipette and 150 
μL DMSO added to each well in order to dissolve the 
purple formazan crystals. A Thermo Scientific Multiskan 
EX microplate photometer was used to measure the 
absorbance of each well at 540 nm. Percentage cell 
viabilities were determined on a logarithmic scale, and 
the half-maximal inhibitory concentration (IC50) was 
determined from a plot of % cell survival versus 
concentration (M). Each of the experiments were 
performed as duplicate technical repeats and triplicate 
experimental repeats, with mean values stated as IC50 ± 
Standard Deviation (SD). 
1.6 Statistical analysis 
GraphPad was used to perform a Student T-test and 
determine the significance of the results, whereby 
probability values less than 0.05 (p < 0.05) are 
significantly statistically different. 
Results and Discussion 
Synthesis and Characterisation 
 
 
A range of precious metal complexes have been 
synthesised, where complexes 2-4 and 7-8 have been 
previously reported by Willans and co-workers (Figure 
1).[37–39] Using similar reactions, we report herein the 
synthesis of a new benzyl tethered ligand (ligand 1), a p-
cymene Ru(II) complex (1) and a Cp* Rh(III) complex (6) 
incorporating ligand 1, and a COD Ir(III) complex (5) with 
a previously published carbaboranyl tethered NHC ligand 
(Scheme 1).[37] All compounds were characterised by 
NMR spectroscopy, high-resolution mass spectrometry 
and where possible single X-ray crystallography. Single 
crystals of complex 6 were obtained from vapour 
diffusion of acetone/ pentane, to yield red crystals 
(Figure 2). The complex crystallises in a monoclinic crystal 
system and solution refinement was performed in the 
space group C2/c. The average Rh1-Cl1 bond lengths are 
2.46-2.48 Å and are significantly longer than the 
previously reported carbaboranyl complex 8,[38] where 
the Rh-Cl bond length is reported as 2.156(3) Å. However, 
the metal carbene (Rh-C1) bond length of 2.048(6) Å is 
similar to complex 8, which was reported as 2.036(3) Å. 
The angles of 86.73(5)-94.91(18)° suggests a pseudo 
octahedral geometry, which is common for these “piano-
stool” complexes.
Figure 1 Structures of ruthenium complexes 1-2, iridium complexes 3-5 and rhodium complexes 6-8, incorporating a benzyl or carboranyl tethered N-
heterocyclic ligand. The new complexes reported in this work are highlighted in dark blue.
Scheme 1 Synthesis of the benzyl tether NCH ligand (ligand 1), p-cymene 
Ru(II) complex 2, COD Ir(I) complex 5 and Cp* Rh(III) complex 6. 
Figure 2 Molecular structures of complex 6. Hydrogen atoms have been 
omitted for clarity and displacement ellipsoids are at the 50% probability 
level. 
Stability in DMSO 
As the chemosensitivity studies were conducted in 
dimethylsulfoxide (DMSO), the stability of the complexes 
has been measured in d6-DMSO over 72 h at room 
temperature. All complexes remain stable in DMSO over 
this time period with no changes observed for the 
complexes’ resonances. However, for all of the 
carbaboranyl tethered complexes (2, 4, 7 and 8), a 
resonance is observed at ~6.5 ppm which increases over 
time (Figure 3A). 
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Figure 3 Stability studies of complex 8 measured by NMR spectroscopy over 72 h; A) 1H NMR spectroscopy and B) 11B NMR spectroscopy  
This resonance is broad in complexes 2 and 4 and 
relatively sharp in complexes 7 and 8, yet we have not 
been able to assign this resonance. The 11B NMR spectra 
was also recorded over 72 h and shows no changes or 
additional resonances within the range of -100 to +100 
ppm for all of the carbaboranyl tethered complexes 
(Figure 3B). 
Chemosensitivity studies after 96 hours 
Cell viability studies were conducted using the MTT assay, 
to assess the cytotoxicity of the Ru (1-2), Ir (3-5) and Rh 
complexes (6-8) (Figure 1). The clinically approved 
platinum complexes cisplatin (CDDP), carboplatin (CARB) 
and oxaliplatin (OXA) were screened for comparison. All 
compounds were screened against HCT116 p53+/+, 
A2780, A2780cisR and MCF-7 after a 96 hour incubation 
period. The values are averages from two technical 
repeats and three experimental repeats, and stated in 
Table 1 (Figure S8). 
On comparison of the ruthenium complexes (1 and 2), 
there are significant increases in the cytotoxicity when 
replacing the benzyl group (1) for the carbaboranyl group 
(2). The benzyl p-cymene Ru(II) complex 1 has low to no 
toxicity against the range of cell lines (IC50 values 71 ± 3 to 
>100 µM), whilst the addition of carbaboranyl (2) 
increases the cytotoxicity by up to >18-fold against 
A2780cisR (p < 0.05). However, it can be noted that 
though complex 2 has increased cytotoxicity against most 
cell lines (9.1-18.3x, p < 0.05), it remains non-toxic 
towards MCF-7 (IC50 >100 µM), which may be a helpful 
feature towards future investigations on structure-
activity relationships and cancer cell selectivity. 
Comparing the same functionalised NHCs on Cp* Rh(III) 
complexes shows a similar effect, whereby the 
carbaboranyl Cp* Rh(III) complex 7 has >8.8-fold increase 
in cytotoxicity when compared to the benzyl Cp* Rh(III) 
complex 6. However, the effects are only moderate in 
comparison to the Ru analogues 2 and 1, with values 
increasing by 1.1-8.9x (p < 0.05). It has been previously 
noted that Cp* Rh(III)-NHC complexes outperform the 
analogues p-cymene Ru(II)-NHC complexes (IC50 > 100 
M), with up to an 11-fold increase in cytotoxicity.[44] 
However, the reverse trends have been observed with 
coordinating ligands other than the NHCs.[45] We are 
currently unable to comment on the effects for the 
analogues Cp* Ir(III)-NHC complexes, and reports 
suggests the ligand will play a large role in the observed 
cytotoxicity values.[46,47] 
Complexes 3 and 4 are Cp* Ir(III) complexes incorporating 
a carbaboranyl tethered NHC and are moderately to 
highly cytotoxic against all cell lines. Complex 4 has a 
cyclometallated carbaboranyl moiety and is a mixture of 
Ccarbaboranyl-Bcarbaboranyl and Ccarbaboranyl-Ccarbaboranyl, (Figure 1), 
which could not be synthetically separated. On analysis 
of the results, the cycometallation of the carbaboranyl 
increases the cytotoxicity of the complex by >3.9x against 
A2780, and between 1.3-3.0x for other cell lines. The non 
cyclometallated complex 3 was further modified by 
synthesising the COD Ir(I)-NHC complex 5, which again 
increased the cytotoxicity values. The most promising 
result was observed against A2780cisR, where complex 5 
exhibited >4.6-fold increase in cytotoxicity when 
compared to the Cp* Ir(III) complex 3.  
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Table 1 IC50 values for cisplatin (CDDP), carboplatin (CARB), oxaliplatin (OXA) and complexes 1-8 against cancer cell lines HCT116 p53+/+, A2780, A2780cisR, 
MCF-7 and normal cell line PNT2. All values are stated as mean values from duplicate technical repeats and triplicate experimental repeats, with selectivity 
indices (SI) for cancerous cells in parentheses.  
 IC50 values (M) ± SD 
 HCT116 p53+/+ A2780 A2780cisR MCF-7 PNT2 
CDDP 1.5 ± 0.1 (5.7) 1.3 ± 0.1 (6.4) 14 ± 1 (0.6) 1.5 ± 0.2 (5.6) 8.5 ± 0.4 
CARB 6.0 ± 0.2 (4.4) 17 ± 1 (1.6) >100 (0.3*) >100 (0.3*) 27 ± 2 
OXA 0.445 ± 0.002 (2.9) 0.505 ± 0.002 (2.6) 2.09 ± 0.03 (0.6 2.6 ± 0.2 (0.5) 1.3 ± 0.2 
1 >100 (n.d.) 71 ± 3 (1.4*) 74 ± 1 (1.4) >100 (n.d.) >100 
2 11.0 ± 0.7 (0.7) 4.4 ± 0.3 (1.9) 4.0 ± 0.2 (2.0) >100 (0.08*) 8.2 ± 0.4 
3 24 ± 2 (1.4) 6.4 ± 0.2 (5.2) 14.9 ± 0.8 (2.2) 66 ± 1 (0.5) 33.23 ± 0.06 
4 7.9 ± 0.4 (1.5) 1.6 ± 0.2 (7.1) 6.9 ± 0.2 (1.7) 49 ± 1 (0.2) 12 ± 1 
5 8.2 ± 0.2 (1.3) 2.15 ± 0.09 (5.1) 3.2 ± 0.3 (3.5) 31 ± 1 (0.4) 11 ± 1 
6 >100 (0.9*) 5.6 ± 0.5 (15.4) 19.1 ± 0.3 (4.5) 65 ± 2 (1.3) 87 ± 2 
7 11.3 ± 0.3 (1.5) 5.2 ± 0.4 (3.3) 9.5 ± 0.3 (1.8) 47 ± 3 (0.4) 17.2 ± 0.7 
8 9.0 ± 0.3 (1.4) 3.3 ± 0.3 (3.7) 10.2 ± 0.4 (1.2) 14.1 ± 0.3 (0.9) 12.8 ± 0.8 
* denotes minimum SI values, as at least one IC50 value is greater than the tested threshold of 100 M 
n.d. denotes SI values which could not be determined, as both IC50 values are greater than the tested threshold of 100 M 
 
Complexes 7 and 8 are the rhodium analogues of the 
iridium complexes 3 and 5, where 7 is the Cp* Rh(III)-
carbaboranyl-NHC complex and 8 is the COD Rh(I)-
carbaboranyl-NHC complex. As with the iridium 
analogues, there is a general increase in the cytotoxicity 
when changing from Cp* Rh(III) to COD Rh(I), with values 
increasing between 1.1-3.2-fold. However, the same 
trend is not observed against A2780cisR, and complexes 
7 and 8 exhibit the similar cytotoxicity values (p > 0.05). 
Sensitivity Factor 
The IC50 values for CDDP, CARB, OXA and complexes 1-8 
were compared for the human ovarian carcinoma cell 
lines A2780 and A2780cisR. In order to address the 
possibility of these complexes to circumvent the issues of 
cisplatin-resistance in cells, the IC50 values are presented 
as sensitivity ratios (SRs). These values were calculated by 
dividing the IC50 value in A2780 by the IC50 value in 
A2780cisR, where SR values >1 indicate a sensitivity for 
the cisplatin-resistant cell line A2780cisR (Figure 4). 
Ruthenium complexes 1 and 2 have SR values of ~1, and 
have the potential to treat tumours which are resistant to 
cisplatin. As expected, the platinum complexes are not 
sensitive to this resistant cell line (SR < 0.3) and CDDP has 
a 10-fold decrease in cytotoxicity. 
Selectivity Index 
One of the drawbacks with platinum-based drugs is the 
lack of selectivity towards cancerous cells, where most 
platinum complexes have high cytotoxicity towards 
normal cell types as well as cancerous cells. This not only 
causes side effects in patients, but this dose-limiting 
toxicity can have significant impact on the drug’s 
effectiveness. The clinical drugs CDDP, CARB and OXA 
and complexes 1-8 have been screened against normal 
prostate cells (PNT2), in order to provide an indication of 
their selectivity (Table 1). The complexes all show 
moderate to high selectivity against this normal cell line, 
though to a lesser degree than towards the cancerous cell 
lines. It should be noted that the benzyl Cp* Rh(III) 
complex 6, has the lowest cytotoxicity of the library, with 
an IC50 value of 87 ± 2. Importantly, this complex is >10x, 
>3x and >67x less cytotoxic than CDDP, CARB and OXA, 
respectively (p < 0.05). 
Figure 4 Sensitivity Ratio (SR) for CDDP, CARB, OXA and complexes 1-8 
when comparing the potency against A2780 and A2780cisR. SR > 1 shows 
sensitivity for A2780cisR, SR = 1 shows equitoxicity and SR < 1 shows 
sensitivity for A2780 
 
 
The results are presented as a selectivity index (SI) and 
are shown in Figure 5 and in the parenthesis of Table 1. 
These values are calculated by dividing the IC50 value in 
the normal cell type by the IC50 value in the cancerous cell 
type. Some of the values are stated as minimum values 
(*, see Table 1 footnote), as at least one IC50 was >100 
M. Some values could not be determine (n.d., see Table 
1 footnote) as both IC50 values were >100 M. The SI 
values which are >1 indicate a selectivity towards the 
cancerous cell line. 
Figure 5 Selectivity Index (SI) for CDDP, CARB, OXA, complexes 1-8 when 
comparing the normal cell line PNT2. SI > 1 shows selectivity for the cancer 
cell lines, SI = 1 show equitoxicity for cancerous and normal cell lines, and SI 
< 1 shows selectivity for the normal cell line PNT2 
The platinum complexes have varying selectivity, with 
CDDP having the most promising SI values, ranging from 
0.6 (A2780cisR) to 6.4 (A2780). Complexes 1-8 have no 
selectivity for the cell lines HCT116 p53+/+ or MCF-7, with 
SI values approximately 1. The complexes are moderately 
selective for the cisplatin-resistant ovarian carcinoma cell 
line, A2780cisR, with SI values ranging from 1.2-4.5 (p < 
0.05). Importantly, these selectivity values are up to 7.5x, 
17x and 7.4x greater than CDDP, CARB and OXA, 
respectively. The highest degree of selectivity is observed 
against the cisplatin-sensitive ovarian carcinoma cell line, 
A2780, where the SI values range between 1.9-15.4. 
Generally, the complexes reported herein are up to 2.4x, 
9.6x and 6.0x more selective than CDDP, CARB and OXA, 
respectively. 
The SI values were calculated for complexes 1-8 in 
comparison with CDDP, CARB and OXA. The results for 
CDDP and CARB are shown in Figure 6A and Figure 6B, 
respectively, however, the complexes were completely 
non-selective over OXA (all SI <0.6, Figure S9) and so this 
data is not presented. When comparing the IC50 values 
with CDDP, there is no selectivity (SI <1) for any of 
complexes 1-8 against HCT116 p53+/+, A2780, MCF-7 or 
PNT2, showing CDDP still outperforms these complexes. 
However, there is a general trend whereby the A2780cisR 
cell line is more sensitive to the metal-carbaboranyl 
complexes 2-5 and 7-8, and are up to 4.4x more selective 
than this leading clinical drug (Figure 6A). The results 
were compared to CARB, and generally HCT116 p53+/+ 
and PNT2 are less sensitive to complexes 1-8. However, 
significant increases in sensitivity were observed against 
A2780, A2780cisR and MCF-7. In particular, complexes 
have SI values up to 7.9, 31.2 and 7.1 against these 
respective cell lines. The most significant result was 
observed for complex 5, the carbaboranyl COD Ir(I) 
complex, which is highly selective against the A2780cisR 
cell line, with an SI value >31.2 (Figure 6B). 
 
Figure 6 Selectivity Index (SI) for complexes 1-8 when the IC50 values of each are compared to A. cisplatin (CDDP) and B. carboplatin (CARB). SI > 1 shows 
selectivity for complexes 1-8, SI = 1 shows equitoxicity, and SI < 1 shows selectivity for the platinum compounds CDDP or CARB. 
Conclusions 
We have presented the synthesis of a new benzyl 
tethered NHC ligand (ligand 1) and three new precious 
metal complexes incorporating either a benzyl tethered 
NHC ligand (1, Ru; 6, Rh) or a carbaboranyl tethered NHC 
ligand (5, Ir). Additionally, we report the single crystal X-
ray structure for the benzyl tether NHC rhodium complex 
6, and show the bond lengths and angles are similar to 
those previously reported by Willans and co-workers. A 
library of eight precious metal complexes (1-2, Ru; 3-5, Ir; 
6-8, Rh) has been synthesised and NMR spectroscopy 
 
 
studies show they all remain stable in DMSO at room 
temperature over 72 h. In vitro chemosensitivity assays 
were conducted against HCT116 p53+/+, A2780, 
A2780cisR, MCF-7 and PNT2, and show a general trend 
whereby changing the tethered NHC ligand from benzyl 
to carbaboranyl increases the complexes potency. The 
most significant results was observed for the ruthenium 
p-cymene complex, whereby the addition of the 
carbaboranyl moiety (2) increases the potency by >18-
fold against A2780cisR (compared to 1). It was also noted 
that changing from Cp*M(III) to COD M(I) also increases 
the potency of the complexes, and against A2780cisR, the 
COD Ir(I) complex (5) is >4.6-fold more cytotoxic than the 
Cp* Ir(III) (3). The complexes are moderately cytotoxic 
towards normal cells (PNT2), however, it should be 
highlighted that the benzyl tethered NHC Cp* Rh(III) 
complex (6), has the lowest cytotoxicity of the library (IC50 
= 87 ± 2 µM) towards normal cells and is >10x, >3x and 
>67x less cytotoxic than CDDP, CARB and OXA, 
respectively. Some of our complexes are more cytotoxic 
than either CDDP or CARB, with significantly increased 
sensitivity against A2780, A2780cisR and MCF-7. 
Complexes have selectivity indices (SI) up to 7.9, 31.2 and 
7.1 against these cell lines. The most significant result was 
observed for complex 5, the carbaboranyl tethered COD 
Ir(I)-NHC complex, which is >31x more potent than CARB 
against A2780cisR. Conclusively, this highlights a 
potentially different in vitro mode of action when 
compared to the clinical platinum drugs, which could be 
important in overcoming the current toxicity issues. 
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